F088 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
DESCRIPTION
This session will provide guidance for the management of hidradenitis suppurativa in challenging scenarios including in the setting of treatment failures, drug-induced rashes, and in pregnancy. Tips for management of patients with milder disease will be discussed, along with strategies to optimize use of biologics and small molecule inhibitors for moderate-to-severe disease. Procedures for HS that can be done in the office, and when to reach for them, will be reviewed. Practical tips and pertinent evidence from the literature will be discussed to help inform future decision-making in HS clinic visits.
LEARNING OBJECTIVES
Identify strategies to optimize use of biologic and small molecule inhibitors in the management of hidradenitis suppurativa
Utilize therapeutic drug monitoring to guide treatment switch decisions
Describe procedures that can be performed in the outpatient setting for patients with HS
SCHEDULE
3:30 PM
Procedure and Wound Care Tips for HS
Steven Daniel Daveluy, MD, FAAD
3:50 PM
Tips and Tricks for Managing Milder HS
Katrina Lee, MD, FAAD
4:10 PM
Strategies to Optimize Use of Biologics and Small Molecule Inhibitors for HS
Vivian Shi, MD, FAAD
4:30 PM
Therapeutic Drug Monitoring & Treatment of Paradoxical Rashes in HS
4:50 PM
HS and Pregnancy
Jennifer Lin Hsiao, MD, FAAD
5:10 PM
Faculty Q&A
DIRECTOR
Jennifer Lin Hsiao, MD, FAAD
Keck School of Medicine, University of Southern California
SPEAKERS
Steven Daniel Daveluy, MD, FAAD
Wayne State University School of Medicine
Katrina Lee, MD, FAAD
Vivian Shi, MD, FAAD
University of Washington, Seattle
DISCLOSURES
Steven Daniel Daveluy, MD, FAAD
AbbVie – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Incyte – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Insmed – Investigator(Grants/Research Funding); Leo Pharma – Advisory Board(Honoraria), Investigator(Grants/Research Funding); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron – Investigator(Grants/Research Funding); Sanofi – Investigator(Grants/Research Funding); Takeda Pharmaceuticals USA Inc – Investigator(Grants/Research Funding); UCB – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Avalo – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); Merck – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); Spyre Therapeutics – Consultant (1099 relationship)(Fees); UCB – Consultant(Fees), Speaker(Fees);
Katrina Lee, MD, FAAD
Incyte – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Novartis – Advisory Board(Honoraria); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding);
Vivian Shi, MD, FAAD
AbbVie – Advisory Board(Fees), Speaker(Fees); Alumis – Advisory Board(Honoraria); Aristea Therapeutics – Advisory Board(Fees); Bain Capital – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Advisory Board(Fees); Burt's Bees – Consultant(Fees); Ceraclere – Consultant (1099 relationship)(Fees); Dematology Foundation – Other(Grants/Research Funding); Demira – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly and Company – Advisory Board(Fees); Foundation of Atopic Dermatitis – Other(Grants/Research Funding); Galderma – Advisory Board(Fees); Genentech, Inc. – Advisory Board(Honoraria); Global Parents for Eczema Research – Consultant(No Compensation Received); GpSkin – Consultant(Fees); HS Foundation – Board of Directors(No Compensation Received); Incyte – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); LearnHealth/LearnSkin – Other(Fees), Stockholder(Stock); Leo Pharma – Consultant (1099 relationship)(Fees); Menlo Therapeutics – Advisory Board(Fees); National Eczema Association – Consultant (1099 relationship)(Honoraria), Speaker(No Compensation Received); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees); Polyfins, Inc – Consultant (1099 relationship)(Fees); Regeneron – Speaker(Fees); Sanofi Genzyme – Advisory Board(Fees), Speaker(Fees); Skin Actives Scientific – Other(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees); UCB Pharma – Advisory Board(Honoraria);